Umoja Biopharma Announces FDA Clearance of IND for UB-VV400, First Known CD22-Directed In Vivo CAR T for Relapsed/Refractory B Cell Malignancies

Umoja Biopharma received FDA clearance for its IND for UB-VV400, the company's lead in vivo CD22-directed CAR T therapy targeting relapsed/refractory B cell malignancies, advancing its clinical pipeline toward first patient dosing.